Ratings by UBS (John Sourbeer)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/7/2025 | 10X Genomics | TXG | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2025 | 10X Genomics | TXG | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/7/2025 | Qiagen NV | QGEN | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/25/2025 | ICON plc | ICLR | Maintain | Buy (Buy) |
|
Details | ||
| 5/13/2025 | 10X Genomics | TXG | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/24/2025 | Thermo Fisher Scientific | TMO | Maintain | Buy (Buy) |
|
Details | ||
| 4/1/2025 | CryoPort | CYRX | Maintain | Buy (Buy) |
|
Details | ||
| 3/24/2025 | CryoPort | CYRX | Upgrade | Buy (Neutral) |
5.69 (16.17) |
184.18% | Details | |
| 3/21/2025 | Maravai LifeScience Holdings Inc. | MRVI | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/7/2025 | Stevanato Group S.p.A. | STVN | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/21/2025 | ICON plc | ICLR | Maintain | Buy (Buy) |
|
Details | ||
| 2/14/2025 | Pacific Biosciences of California | PACB | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/13/2025 | 10X Genomics | TXG | Maintain | Neutral (Neutral) |
|
Details | ||
| 1/31/2025 | Thermo Fisher Scientific | TMO | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2024 | Pacific Biosciences of California | PACB | Downgrade | Neutral (Buy) |
2.30 (1.56) |
-32.17% | Details | |
| 11/8/2024 | Maravai LifeScience Holdings Inc. | MRVI | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2024 | CryoPort | CYRX | Maintain | Neutral (N/A) |
|
Details | ||
| 10/30/2024 | 10X Genomics | TXG | Maintain | Neutral (N/A) |
|
Details | ||
| 10/25/2024 | ICON plc | ICLR | Maintain | Buy (N/A) |
|
Details | ||
| 10/18/2024 | CryoPort | CYRX | Maintain | Neutral (N/A) |
|
Details | ||
| 9/16/2024 | Thermo Fisher Scientific | TMO | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2024 | 10X Genomics | TXG | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2024 | Maravai LifeScience Holdings Inc. | MRVI | Maintain | Neutral (N/A) |
|
Details | ||
| 8/7/2024 | CryoPort | CYRX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/2/2024 | Qiagen NV | QGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 6/18/2024 | Qiagen NV | QGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/1/2024 | 10X Genomics | TXG | Maintain | Neutral (N/A) |
|
Details | ||
| 3/20/2024 | Singular Genomics | OMIC | Maintain | Neutral (N/A) |
|
Details | ||
| 3/15/2024 | CryoPort | CYRX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/8/2024 | Stevanato Group S.p.A. | STVN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/8/2024 | Medpace | MEDP | Maintain | Buy (N/A) |
|
Details | ||
| 3/5/2024 | Akoya Biosciences Inc | AKYA | Maintain | Buy (N/A) |
|
Details | ||
| 2/21/2024 | 10X Genomics | TXG | Maintain | Neutral (N/A) |
|
Details | ||
| 2/16/2024 | Pacific Biosciences of California | PACB | Maintain | Buy (N/A) |
|
Details | ||
| 2/15/2024 | Medpace | MEDP | Upgrade | Buy (Neutral) |
364.10 (320.58) |
-11.95% | Details | |
| 2/6/2024 | Catalent | CTLT | Downgrade | Neutral (Buy) |
54.51 (63.48) |
16.46% | Details | |
| 2/1/2024 | Thermo Fisher Scientific | TMO | Maintain | Buy (N/A) |
|
Details | ||
| 1/2/2024 | Qiagen NV | QGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/2/2024 | Pacific Biosciences of California | PACB | Maintain | Buy (N/A) |
|
Details | ||
| 1/2/2024 | CryoPort | CYRX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/15/2023 | Thermo Fisher Scientific | TMO | Maintain | Buy (N/A) |
|
Details | ||
| 11/17/2023 | Pacific Biosciences of California | PACB | Upgrade | Buy (Neutral) |
7.81 (1.56) |
-80.03% | Details | |
| 11/9/2023 | CryoPort | CYRX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2023 | Maravai LifeScience Holdings Inc. | MRVI | Maintain | Neutral (N/A) |
|
Details | ||
| 11/7/2023 | 10X Genomics | TXG | Maintain | Neutral (N/A) |
|
Details | ||
| 11/1/2023 | Qiagen NV | QGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/26/2023 | Thermo Fisher Scientific | TMO | Maintain | Buy (N/A) |
|
Details | ||
| 10/25/2023 | Medpace | MEDP | Maintain | Neutral (N/A) |
|
Details | ||
| 10/12/2023 | Singular Genomics | OMIC | Maintain | Neutral (N/A) |
|
Details | ||
| 10/12/2023 | NanoString Tech | NSTG | Maintain | Buy (N/A) |
|
Details | ||
| 10/12/2023 | Akoya Biosciences Inc | AKYA | Maintain | Buy (N/A) |
|
Details | ||
| 9/29/2023 | Maravai LifeScience Holdings Inc. | MRVI | Maintain | Neutral (N/A) |
|
Details | ||
| 9/28/2023 | Stevanato Group S.p.A. | STVN | Maintain | Neutral (N/A) |
|
Details | ||
| 9/21/2023 | Stevanato Group S.p.A. | STVN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/30/2023 | Catalent | CTLT | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2023 | CryoPort | CYRX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/10/2023 | Singular Genomics | OMIC | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2023 | Qiagen NV | QGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2023 | Maravai LifeScience Holdings Inc. | MRVI | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2023 | Akoya Biosciences Inc | AKYA | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2023 | 10X Genomics | TXG | Maintain | Neutral (N/A) |
|
Details | ||
| 7/28/2023 | ICON plc | ICLR | Maintain | Buy (N/A) |
|
Details | ||
| 7/18/2023 | CryoPort | CYRX | Downgrade | Neutral (Buy) |
15.04 (16.17) |
7.51% | Details | |
| 7/10/2023 | Singular Genomics | OMIC | Maintain | Neutral (N/A) |
|
Details | ||
| 7/10/2023 | Maravai LifeScience Holdings Inc. | MRVI | Maintain | Neutral (N/A) |
|
Details | ||
| 7/10/2023 | ICON plc | ICLR | Maintain | Buy (N/A) |
|
Details | ||
| 6/13/2023 | Catalent | CTLT | Maintain | Buy (N/A) |
|
Details | ||
| 6/6/2023 | CryoPort | CYRX | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2023 | Singular Genomics | OMIC | Maintain | Neutral (N/A) |
|
Details | ||
| 5/9/2023 | Akoya Biosciences Inc | AKYA | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | Qiagen NV | QGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/5/2023 | Stevanato Group S.p.A. | STVN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/4/2023 | 10X Genomics | TXG | Maintain | Neutral (N/A) |
|
Details | ||
| 4/17/2023 | Catalent | CTLT | Maintain | Buy (N/A) |
|
Details | ||
| 4/10/2023 | Maravai LifeScience Holdings Inc. | MRVI | Maintain | Neutral (N/A) |
|
Details | ||
| 4/10/2023 | Medpace | MEDP | Maintain | Neutral (N/A) |
|
Details | ||
| 4/10/2023 | 10X Genomics | TXG | Maintain | Neutral (N/A) |
|
Details | ||
| 4/10/2023 | Stevanato Group S.p.A. | STVN | Maintain | Neutral (N/A) |
|
Details | ||
| 4/10/2023 | CryoPort | CYRX | Maintain | Buy (N/A) |
|
Details | ||
| 3/6/2023 | Singular Genomics | OMIC | Maintain | Neutral (N/A) |
|
Details | ||
| 3/6/2023 | Stevanato Group S.p.A. | STVN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/27/2023 | Syneos | SYNH | Maintain | Neutral (N/A) |
|
Details | ||
| 2/24/2023 | ICON plc | ICLR | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2023 | CryoPort | CYRX | Maintain | Buy (N/A) |
|
Details | ||
| 2/14/2023 | Catalent | CTLT | Maintain | Buy (N/A) |
|
Details | ||
| 2/9/2023 | Qiagen NV | QGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/2/2023 | Thermo Fisher Scientific | TMO | Maintain | Buy (N/A) |
|
Details | ||
| 2/2/2023 | NanoString Tech | NSTG | New Coverage | Buy (N/A) |
11.35 (0.11) |
-99.03% | Details | |
| 2/2/2023 | Akoya Biosciences Inc | AKYA | New Coverage | Neutral (N/A) |
11.64 (1.29) |
-88.92% | Details | |
| 2/2/2023 | 10X Genomics | TXG | New Coverage | Neutral (N/A) |
47.59 (42.73) |
-10.21% | Details | |
| 1/5/2023 | Maravai LifeScience Holdings Inc. | MRVI | Downgrade | Neutral (Buy) |
13.69 (6.09) |
-55.51% | Details | |
| 11/9/2022 | Qiagen NV | QGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2022 | Syneos | SYNH | Maintain | Neutral (N/A) |
|
Details | ||
| 11/8/2022 | Singular Genomics | OMIC | Maintain | Neutral (N/A) |
|
Details | ||
| 10/27/2022 | Medpace | MEDP | Upgrade | Neutral (Sell) |
221.50 (538.23) |
142.99% | Details | |
| 10/6/2022 | CryoPort | CYRX | Maintain | Buy (N/A) |
|
Details | ||
| 10/6/2022 | Catalent | CTLT | Maintain | Buy (N/A) |
|
Details | ||
| 9/7/2022 | Syneos | SYNH | New Coverage | Neutral (N/A) |
58.28 (42.98) |
-26.25% | Details | |
| 9/7/2022 | ICON plc | ICLR | New Coverage | Buy (N/A) |
206.74 (167.72) |
-18.87% | Details | |
| 9/7/2022 | Medpace | MEDP | New Coverage | Sell (N/A) |
145.55 (538.23) |
269.79% | Details | |
| 8/17/2022 | Singular Genomics | OMIC | Downgrade | Neutral (Buy) |
4.31 (20.01) |
364.27% | Details | |
| 8/9/2022 | Stevanato Group S.p.A. | STVN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/5/2022 | CryoPort | CYRX | Maintain | Buy (N/A) |
|
Details | ||
| 5/3/2022 | Catalent | CTLT | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2022 | Qiagen NV | QGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2022 | Singular Genomics | OMIC | Maintain | Buy (N/A) |
|
Details | ||
| 2/17/2022 | Ortho Clinical Diagnostics | OCDX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/6/2022 | Singular Genomics | OMIC | Maintain | Buy (N/A) |
|
Details | ||
| 12/28/2021 | Ortho Clinical Diagnostics | OCDX | Downgrade | Neutral (Buy) |
21.16 (17.63) |
-16.68% | Details | |
| 11/5/2021 | Qiagen NV | QGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/28/2021 | Thermo Fisher Scientific | TMO | Maintain | Buy (N/A) |
|
Details | ||
| 10/15/2021 | Stevanato Group S.p.A. | STVN | Maintain | Neutral (N/A) |
|
Details | ||
| 9/21/2021 | Thermo Fisher Scientific | TMO | Maintain | Buy (N/A) |
|
Details | ||
| 8/31/2021 | Catalent | CTLT | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2021 | Stevanato Group S.p.A. | STVN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/10/2021 | Stevanato Group S.p.A. | STVN | New Coverage | Neutral (N/A) |
20.00 (19.59) |
-2.05% | Details | |
| 8/5/2021 | Ortho Clinical Diagnostics | OCDX | Maintain | Buy (N/A) |
|
Details | ||
| 7/23/2021 | Qiagen NV | QGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/6/2021 | Ortho Clinical Diagnostics | OCDX | Maintain | Buy (N/A) |
|
Details | ||
| 3/15/2021 | CryoPort | CYRX | New Coverage | Buy (N/A) |
57.35 (15.04) |
-73.78% | Details | |
| 2/22/2021 | Ortho Clinical Diagnostics | OCDX | New Coverage | Buy (N/A) |
16.98 (17.63) |
3.83% | Details |
